2016
Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Hartley M, Bourreau E, Rossi M, Castiglioni P, Eren R, Prevel F, Couppié P, Hickerson S, Launois P, Beverley S, Ronet C, Fasel N. Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A. PLOS Pathogens 2016, 12: e1005852. PMID: 27658195, PMCID: PMC5033371, DOI: 10.1371/journal.ppat.1005852.Peer-Reviewed Original ResearchIL-17AMurine modelMetastatic leishmaniasisDisease chronicityHuman patientsInflammatory cytokines IL-17AIL-17A inhibitionPotent innate immunogenPresence of LRV1Cytokines IL-17AAbsence of IFNMetastatic complicationsImmunologic mechanismsStandard therapyCytokines IFNPrognostic valueOpen ulcerationDisease outcomeCutaneous leishmaniasisSecondary sitesSignificant associationLeishmania parasitesTherapeutic promiseLeishmaniasisLRV1
2014
The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis
Hartley M, Drexler S, Ronet C, Beverley S, Fasel N. The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends In Parasitology 2014, 30: 412-422. PMID: 24954794, PMCID: PMC4287268, DOI: 10.1016/j.pt.2014.05.006.Peer-Reviewed Original ResearchConceptsInnate immune systemImmune systemSelf-healing cutaneous lesionsPattern recognition receptorsFacial mucosaMetastatic leishmaniasisMetastatic diseasePapular rashCutaneous lesionsSuch diverse pathologiesCutaneous systemHost immunocompetenceGranulomatous nodulesParasitic infectionsRecognition receptorsPotential associationCutaneous leishmaniasesDiverse pathologiesMillions of peoplePathologyMultiple secondary sitesSecondary sitesRashUlcerationMetastasis